Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095484 · ClinicalTrials.gov registry record
Named Patient Program With Rotigotine Transdermal System
A clinical trial of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine, sponsored by UCB Pharma.
- Completed
- Registry status
- 520
- Enrollment target
- 20
- Study locations
NCT01095484: Completed study of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine, sponsored by UCB Pharma.
NCT01095484 is a study of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine that has completed, run by UCB Pharma. The registered enrollment target is 520 participants. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01095484, a study of Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.
Primary Outcome
Adverse events as reported spontaneously by the subject or as assessed by the investigator at the maintenance visits (about every three months)
Conditions Studied
Interventions
- DRUG Rotigotine patch
Study Locations (20)
California
- 036 - Berkeley
- 024 - Fountain Valley
- 034 - Irvine
- 019 - Los Angeles
- 040 - Orange
- 076 - Sunnyvale
Florida
- 070 - Atlantis
- 002 - Boca Raton
- 031 - Clearwater
- 028 - Largo
- 075 - Ormond Beach
Alabama
- 088 - Birmingham
- 082 - Cullman
- 085 - Fairhope
- 014 - Huntsville
Arizona
- 097 - Gilbert
- 003 - Phoenix
- 044 - Phoenix
Colorado
- 035 - Fort Collins
District of Columbia
- 027 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
What the finished NCT01095484 record still lists
NCT01095484 is an observational study that tracks outcomes without assigning an intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine appearing as the primary indexed condition, and to 1 intervention - of which Rotigotine patch is the first listed.
NCT01095484 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01095484 about?
NCT01095484 is a clinical study titled "Named Patient Program With Rotigotine Transdermal System". The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.
What is the current status of trial NCT01095484?
This trial is currently completed. The enrollment target is 520 participants. The study started on 2008-11. Estimated completion is 2012-12.
What conditions does trial NCT01095484 study?
This clinical trial studies the following conditions: Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine.
What interventions are being tested in trial NCT01095484?
The interventions under investigation include: Rotigotine patch (DRUG).
Who is sponsoring clinical trial NCT01095484?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01095484 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia